[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atheroscleroses-intracranial\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atheroscleroses-intracranial":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100547151","plaque-characteristics-predict-recurrent-stroke-in-mca-stroke-patients-100547151",false,"NCT06404242","Plaque Characteristics Predict Recurrent Stroke in MCA Stroke Patients","Plaque Characteristics From Vessel Wall Magnetic Resonance Imaging Predict Recurrent Stroke in Ischemic Stroke Patients Due to Middle Cerebral Artery Stenosis","Inclusion Criteria:\n\n* Patients who had a first-time ischemic stroke due to MCA atherosclerosis stenosis more than 50% and admitted to our hospital within 7 days after onset.\n* Patients are more than 45 years old.\n* Patients had HR-MRI and have done the full stroke workup (including carotid duplex scanning, fasting lipid profile, Holter ECG 24 hours, cardiac ultrasound,...)\n\nExclusion Criteria:\n\n* Patients also have stenosis of the carotid artery (more than 50%) or occulsion on the same side of ischemic stroke\n* Patients also have an ischemic stroke in territories other than MCA territory.\n* Patients had any characteristics that suggested other causes for their stenosis, including moyamoya, dissection, and inflammation on their MRI and HR-MRI.\n* Patients with evidence suggestive of cardioembolism (Atrial fibrillation, decreased EF \\\u003C50%, recent heart attack in 3 weeks, rheumatic valvular heart disease, dilated cardiopathy, sick sinus syndrome, infective endocarditis).\n* Any signs suggestive other causes (non atherosclerosis etiology), including autoimmune disease or increased coagulation state.\n* Patients with severe concomitant disease could affect the 6-month follow-up of the patients.","ALL","45 Years","100 Years",{"count":20,"type":21},75,"ESTIMATED","OBSERVATIONAL","The epidemiology of TOAST classification in Asian patients seems to differ due to the higher rates of large-artery atherosclerosis. The complex pathology of atherosclerosis could lead to recurrent stroke, including shear stress on the endothelium, disturbance of the flow, occlusion at the origin of the perforating artery, and other complications (plaque inflammation, plaque hemorrhage, plaque rupture) that could lead to stroke and recurrent stroke. Therefore, The exact determination of the etiology of stroke due to atherosclerosis is the most critical factor for treatment and prognostic. On the other hand, HR-MRI could be a useful imaging modality to evaluate the characteristics of plaque in stroke patients due to atherosclerosis stenosis, which will help us find out the etiology of stroke. Previous studies have demonstrated its prognosis value in predicting recurrent stroke in the same vascular territory. The investigators hypothesize that with an appropriate evaluation, HR-MRI could help to predict recurrent stroke in the same vascular territory in patients with high-risk plaque characteristics on HR-MRI. These findings could contribute to individual treatment according to etiology.\n\nThe investigators intend to conduct a study to determine the correlation between plaque characteristics and recurrent stroke in the same vascular territory in ischemic stroke patients due to middle cerebral artery stenosis.",[25,26,27,28,29],"High Resolution Vessel Wall Imaging","Recurrent Stroke","Stroke, Mechanism","Atheroscleroses, Intracranial","Stroke, Infarct Pattern","RECRUITING","2026-08-03",{"date":33,"type":34},"2026-08-06","ACTUAL",{"date":36,"type":34},"2024-05-27",{"date":38,"type":21},"2026-12",{"name":40,"class":41},"University Medical Center Ho Chi Minh City (UMC)","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":65,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100550486","phase-3-interleukin-6-receptor-inhibition-for-symptomatic-intracranial-atherosclerosis-100550486","NCT06447701","Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis","Effect of Interleukin-6 Receptor Inhibition for Avoiding Recurrence of Ischemic Stroke in Patients With Symptomatic Intracranial Atherosclerosis: a Double-blind, Randomized, Placebo-controlled Trial","IRIS-sICAS","Inclusion Criteria:\n\n* Male or non-pregnant women with acute stroke symptoms aged over 18 years.\n* Patients having an ischemic stroke or a TIA prior to randomization (Patients having an acute ischemic stroke within 72 hours with NIHSS score≤5 at baseline, or patients having a TIA within 72 hours with Oxfordshire Community Stroke Project on the basis of age, blood pressure, clinical features, and duration of TIA symptoms (ABCD2) score≥4 at baseline).\n* The entry event is attributed to symptomatic atherosclerosis (50-99%) in an intracranial qualifying artery (intracranial carotid artery (C4-7), middle cerebral artery (M1), intracranial vertebral artery or basilar artery) confirmed by CT, MR angiography, or digital subtraction angiography.\n* Informed consent obtained from patients or their legal representatives.\n* Willing to be followed up as required by the clinical study protocol.\n\nExclusion Criteria:\n\n* Thrombolytic therapy or thrombectomy within 24 hours prior to enrollment.\n* Pre-stroke mRS score ≥ 2.\n* Combined or previous intracranial hemorrhage: hemorrhagic stroke, epidural hematoma, subdural hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc.\n* Any of the following unequivocal cardiac source of embolism: chronic or paroxysmal atrial fibrillation, sinus node dysfunction, mitral stenosis, prosthetic heart valves, endocarditis, left ventricular mural thrombus or valvular vegetation, myocardial infarction within three months, dilated cardiomyopathy, spontaneous echogenic defects in the left atrium or an ejection fraction of less than 30%.\n* Intracranial arterial stenosis due to arterial dissection, Moya Moya disease; herpes zoster, varicella zoster or other viral vasculopathy; neurosyphilis; radiation induced vasculopathy; fibromuscular dysplasia; sickle cell disease; neurofibromatosis; post-partum angiopathy; suspected vasospastic process, suspected recanalized embolus; any known vasculitic disease.\n* Extracranial stenosis ≥50%, subclavian arterial stenosis≥50% or subclavian steal syndrome.\n* Previous interventions for intracranial arterial stenosis.\n* Concurrent intracranial tumors, intracranial aneurysms or arteriovenous malformations\n* Neutrophil \\\u003C 2×10 9\u002FL.\n* Platelet \\\u003C 100×10 9\u002FL.\n* Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than 1.5 times the upper limit of normal.\n* Active infections including localized.\n* Evidence of HIV or hepatitis B positivity.\n* Positive tuberculosis-related tests.\n* Concurrent peptic ulcer, diverticulitis or inflammatory bowel disease.\n* Concurrent malignant tumors, recent bone marrow transplant or recent organ transplant.\n* Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg despite blood pressure control.\n* Known allergy to tocilizumab or excipients.\n* Use of immunosuppressive drugs or systemic use of antibiotics.\n* Received any live or live attenuated vaccine within 4 weeks prior to enrollment or plan to receive a live or live attenuated vaccine during the study.\n* History of demyelination or presence of neurological symptoms suggestive of demyelination.\n* Previously existing neurological or psychiatric disorders that could potentially confuse neurological function assessment.\n* An expected survival less than 90 days.\n* Participation in another interventional clinical study.\n* Patients unsuitable for enrollment in the clinical trial according to investigators decision making.","18 Years",{"count":53,"type":21},486,"INTERVENTIONAL",[56],"PHASE3","IRIS-sICAS is a multicenter, randomized, double-blind, placebo-controlled clinical trialis a multicenter, randomized, double-blind, placebo-controlled clinical trial, to assess the safety and efficacy of tocilizumab injection in lowering the incidence of newly diagnosis ischemic stroke and improving prognosis in symptomatic intracranial atherosclerosis patients.",[59,60,61,62,63,64,28],"Brain Diseases","Ischemic Stroke","Ischemia","Stroke","Cerebral Infarction","Atherosclerosis of Artery",[66,67,68,69],"Tocilizumab","Symptomatic intracranial atherosclerotic stenosis","Recurrence","Ischemic stroke","NOT_YET_RECRUITING","2025-07-24",{"date":73,"type":34},"2025-07-28",{"date":75,"type":21},"2025-10-30",{"date":77,"type":21},"2029-06-30",{"name":79,"class":41},"Zhujiang Hospital"]